Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$2.45 USD
+0.09 (3.59%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $2.44 -0.01 (-0.41%) 6:52 PM ET
2-Buy of 5 2
D Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XERS 2.45 +0.09(3.59%)
Will XERS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for XERS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XERS
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
XERS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
Why Xeris (XERS) Might Surprise This Earnings Season
Other News for XERS
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Xeris Biopharma Announces CEO Succession Plan
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Corcept Therapeutics Stock Merits Accumulation
Xeris Pharmaceuticals Shareholders Back Key Proposals and Directors